Physician profile
Danny Chi
NPI 1366917460
$4,155.85
in general payments reported to CMS, 2019-2025
11 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $103 · 2023: $1,015 · 2024: $1,927 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,053.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,585.19 | 2023-2025 | Dovato, Rukobia, Apretude |
| Gilead Sciences, INC. | $986.63 | 2023-2025 | Yeztugo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $750.33 | 2021-2025 | Relistor |
| Merck Sharp & Dohme LLC | $303.23 | 2023-2025 | Pifeltro, Delstrigo, Verquvo |
| Madrigal Pharmaceuticals | $227.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Paratek Pharmaceuticals, INC. | $88.41 | 2025 | Nuzyra |
| Abbvie INC. | $64.50 | 2024-2025 | |
| Pfizer INC. | $50.24 | 2023 | |
| Ibsa Pharma INC. | $39.06 | 2024 | Tirosint, Flector, Licart |
| Janssen Biotech, INC. | $31.04 | 2023 | Symtuza |
| Alkermes, INC. | $29.40 | 2024 | Vivitrol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Chi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.